Suchergebnisse - "Ofran, Yishai"

PubPharm (9)

1

The increasingly blurred line between induction, consolidation and maintenance in acute myeloid leukaemia

enthalten in: British journal of haematology | 2023

von Frisch, A. | Rowe, J. | Ofran, Y.

2

Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia : a real-world analysis

enthalten in: Annals of hematology | 2022

von Wolach, O. | Frisch, A. | Shargian, L. | +11

3

Re-induction versus salvage for D14-resiudal acute myeloid leukemia : A retrospective multi-center study

enthalten in: Leukemia research | 2022

von Frisch, A. | Aumann, S. | Zuckerman, T. | +10

4

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia

enthalten in: Blood cancer journal | 2022

von Pratz, K. | Panayiotidis, P. | Recher, C. | +23

5

Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice

enthalten in: American journal of hematology | 2021

von Apel, A. | Moshe, Y. | Ofran, Y. | +12

6

BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia : An open-label safety and efficacy phase 2a study

enthalten in: Cancer | 2021

von Borthakur, G. | Ofran, Y. | Tallman, M. | +27

7

Venetoclax is safe and efficacious in relapsed/refractory AML

enthalten in: Leukemia & lymphoma | 2020

von Ganzel, C. | Ram, R. | Gural, A. | +16

8

ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia

enthalten in: Scientific reports | 2020

von Hayun, M. | Zaatra, M. | Itzkovich, C. | +8

9

BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction : a phase 1/2a study

enthalten in: Blood advances | 2019

von Zuckerman, T. | Ram, R. | Akria, L. | +14

1
[1]